European journal of cancer (Oxford, England : 1990)HumansMelanomaMaleProto-Oncogene Proteins B-rafFemale
Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma.
Rasmus Haunstrup Døssing, Elisabeth Hesselberg, Anna Burton Clausen, Adam Andrzej Luczak, Mario Presti, Inge Marie Svane, Henrik Schmidt, Lars Bastholt, Marco Donia, Eva Ellebaek
Published: 202610.1016/j.ejca.2025.116200
Abstract
BACKGROUND: BRAF and MEK inhibitors (BRAFi/MEKi) induce high response rates and rapid tumor regression in BRAF-mutated metastatic melanoma. While responses last around 12 months, ≈ 24 % of patients in clinical trials achieve progression-free survival…
Preview only. Read the full abstract at the source